⌘K

Login Start Free

Home/Filings/4/0001562180-24-000395

4//SEC Filing

Landis John B. 4

Accession 0001562180-24-000395

CIK 0001314102other

View on SEC.gov Company Profile

Filed

Jan 8, 7:00 PM ET

Accepted

Jan 9, 8:55 PM ET

Size

9.8 KB

Accession

0001562180-24-000395

Insider Transaction Report

Form 4

Period: 2024-01-05

EyePoint Pharmaceuticals, Inc.EYPT

Director

Transactions

Award
Stock Option (Right to Buy)
2024-01-05+25,014→ 25,014 total
Exercise: $20.40From: 2025-01-05Exp: 2034-01-04→ Common Stock (25,014 underlying)
Award
Stock Option (Right to Buy)
2024-01-05+20,000→ 20,000 total
Exercise: $20.40From: 2025-01-05Exp: 2034-01-04→ Common Stock (20,000 underlying)
Award
Restricted Stock Units
2024-01-05+10,000→ 10,000 total
Exercise: $0.00From: 2025-01-05Exp: 2034-01-04→ Common Stock (10,000 underlying)

Documents

1 file

4
primarydocument.xmlPrimary
PRIMARY DOCUMENT

Issuer

EyePoint Pharmaceuticals, Inc.

CIK 0001314102

Entity typeother

Related Parties

1

filerCIK 0001477283

Filing Metadata

Form type: 4
Filed: Jan 8, 7:00 PM ET
Accepted: Jan 9, 8:55 PM ET
Size: 9.8 KB

View on SEC.gov